NYSE:PKI - PerkinElmer Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$82.41 +0.76 (+0.93 %)
(As of 11/16/2018 10:31 AM ET)
Previous Close$81.65
Today's Range$81.55 - $82.41
52-Week Range$69.21 - $98.33
Volume1,947 shs
Average Volume839,935 shs
Market Capitalization$9.04 billion
P/E Ratio28.56
Dividend Yield0.34%
Beta1.11
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and PerkinElmer. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Current SymbolNYSE:PKI
Previous Symbol
CUSIP71404610
Phone781-663-6900

Debt

Debt-to-Equity Ratio0.73
Current Ratio1.70
Quick Ratio1.18

Price-To-Earnings

Trailing P/E Ratio28.56
Forward P/E Ratio22.89
P/E Growth1.81

Sales & Book Value

Annual Sales$2.26 billion
Price / Sales4.06
Cash Flow$3.9812 per share
Price / Cash20.70
Book Value$23.13 per share
Price / Book3.56

Profitability

EPS (Most Recent Fiscal Year)$2.90
Net Income$292.63 million
Net Margins4.71%
Return on Equity15.04%
Return on Assets6.35%

Miscellaneous

Employees11,000
Outstanding Shares111,240,000
Market Cap$9.04 billion
OptionableOptionable

PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Wednesday, October 24th. Investors of record on Friday, January 18th will be paid a dividend of $0.07 per share on Friday, February 8th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, January 17th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its earnings results on Wednesday, October, 31st. The medical research company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.92 by $0.02. The medical research company had revenue of $674.30 million for the quarter, compared to analysts' expectations of $676.72 million. PerkinElmer had a return on equity of 15.04% and a net margin of 4.71%. The business's revenue for the quarter was up 21.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.73 earnings per share. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY18 earnings guidance on Wednesday, October, 31st. The company provided earnings per share guidance of ~$3.60 for the period, compared to the Thomson Reuters consensus estimate of $3.66. PerkinElmer also updated its FY 2018 guidance to $3.60-3.60 EPS.

What price target have analysts set for PKI?

10 Wall Street analysts have issued 1-year price objectives for PerkinElmer's shares. Their predictions range from $73.36 to $100.00. On average, they expect PerkinElmer's share price to reach $88.1511 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Price Targets for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

Media headlines about PKI stock have been trending positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PerkinElmer earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

Who are some of PerkinElmer's key competitors?

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman, CEO & Pres (Age 62)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 49)
  • Mr. James Corbett, Exec. VP & Pres of Discovery and Analytical Solutions (Age 55)
  • Mr. Prahlad R. Singh, Exec. VP & Pres of Diagnostics (Age 53)
  • Mr. James M. Mock, Sr. VP & CFO

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (10.93%), Select Equity Group L.P. (6.90%), BlackRock Inc. (5.89%), Janus Henderson Group PLC (5.61%), Massachusetts Financial Services Co. MA (3.08%) and Primecap Management Co. CA (2.84%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Institutional Ownership Trends for PerkinElmer.

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Partner Fund Management L.P., Franklin Resources Inc., Allianz Asset Management GmbH, Pictet Asset Management Ltd., Robecosam AG, Janus Henderson Group PLC and First Trust Advisors LP. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan and Robert F Friel. View Insider Buying and Selling for PerkinElmer.

Which major investors are buying PerkinElmer stock?

PKI stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., State Treasurer State of Michigan, Capital Research Global Investors, Sensato Investors LLC, Massachusetts Financial Services Co. MA, Assenagon Asset Management S.A. and Artemis Investment Management LLP. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $82.41.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $9.04 billion and generates $2.26 billion in revenue each year. The medical research company earns $292.63 million in net income (profit) each year or $2.90 on an earnings per share basis. PerkinElmer employs 11,000 workers across the globe.

What is PerkinElmer's official website?

The official website for PerkinElmer is http://www.perkinelmer.com.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  393 (Vote Outperform)
Underperform Votes:  405 (Vote Underperform)
Total Votes:  798
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2018 by MarketBeat.com Staff

Featured Article: S&P 500 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel